Drugs / CART-BCMA
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06056102 | May 2024 → Dec 2028 expected | end stage renal failure, kidney failure | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 1 | NCT05346198 | Mar 2021 → Jul 2022 | plasma cell myeloma | Shanghai Simnova Biotechnology Co.,Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03549442 | May 2018 → Mar 2036 expected | plasma cell myeloma | University of Pennsylvania | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02546167 | Sep 2015 → Aug 2019 | plasma cell myeloma | University of Pennsylvania | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART-BCMA | “autologous T cells expressing BCMA (B-cell maturation antigen)-specific chimeric antigen receptors with tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains (referred to...” NCT03549442 ↗ |
| Action | Deplete | “CAR T cells targeting Bmems and LLPCs eliminates donor-specific allo-antibodies” PMID 38118406 ↗ Dec 2023 |
| Modality | Cell therapy | “autologous T cells lentivirally-transduced with a fully-human, BCMA-specific CAR containing CD3ζ and 4-1BB signaling domains” PMID 30896447 ↗ Mar 2019 |
| Route | Intravenous | “CART-BCMA cells will be given as a split dose intravenous infusion over 3 days.” NCT02546167 ↗ |